Department of Immunology 2nd Faculty of Medicine Charles University and University Hospital Motol Prague 15006 Czech Republic

Department of Paediatric and Adult Rheumatology University Hospital Motol Prague Czech Republic

Lancet Rheumatol. 2023 Mar;5(3):e119. doi: 10.1016/S2665-9913(23)00038-3. PubMed

Zobrazit více v PubMed

Her M, Kavanaugh A. Alterations in immune function with biologic therapies for autoimmune disease. J Allergy Clin Immunol. 2016;137:19–27. PubMed

Ramiro S, Sepriano A, Chatzidionysiou K, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2017;76:1101–1136. PubMed

Mahil SK, Bechman K, Raharja A, et al. Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study. Lancet Rheumatol. 2021 doi: 10.1016/S2665-9913(21)00333-7. published online Nov 9. PubMed DOI PMC

The Lancet Rheumatology COVID-19 vaccine data provide reassurance. Lancet Rheumatol. 2021;3:e605. PubMed PMC

Mahil SK, Bechman K, Raharja A, et al. The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study. Lancet Rheumatol. 2021;3:e627–e637. PubMed PMC

Paces J, Strizova Z, Smrz D, Cerny J. COVID-19 and the immune system. Physiol Res. 2020;69:379–388. PubMed PMC

Dispinseri S, Secchi M, Pirillo MF, et al. Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival. Nat Commun. 2021;12 PubMed PMC

Moor MB, Suter-Riniker F, Horn MP, et al. Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study. Lancet Rheumatol. 2021;3:e789–e797. PubMed PMC

Wajnberg A, Amanat F, Firpo A, et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science. 2020;370:1227–1230. PubMed PMC

Sauer K, Harris T. An effective COVID-19 vaccine needs to engage T cells. Front Immunol. 2020;11 PubMed PMC

Effect of treatment with original or biosimilar adalimumab on SARS-CoV2 vaccination antibody titers

Autoimmunity and hernia mesh: fact or fiction?

SARS-CoV-2-specific humoral and cellular immune responses to BNT162b2 vaccine in Fibrodysplasia ossificans progressiva patients

Immunogenicity and safety of the booster BNT162b2 vaccine in patients with axial spondyloarthritis treated with biological disease-modifying drugs